NCT05160922 2026-03-30Crizotinib Continuation Clinical StudyPfizerPhase 4 Active not recruiting27 enrolled
NCT04094610 2025-11-19A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsTurning Point Therapeutics, Inc.Phase 1/2 Recruiting75 enrolled